Behavior Therapy for Children With Tourette Disorder: A Randomized Controlled Trial | Adolescent Medicine | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.212.130. Please contact the publisher to request reinstatement.
1.
Khalifa N, von Knorring A. Prevalence of tic disorders and Tourette syndrome in a Swedish school population.  Dev Med Child Neurol. 2003;45(5):315-31912729145PubMedGoogle ScholarCrossref
2.
Centers for Disease Control and Prevention (CDC).  Prevalence of diagnosed Tourette syndrome in persons aged 6–17 years—United States, 2007.  MMWR Morb Mortal Wkly Rep. 2009;58(21):581-58519498335PubMedGoogle Scholar
3.
Leckman JF, Bloch MH, King RA, Scahill L. Phenomenology of tics and natural history of tic disorders. In: Walkup JT, Mink JW, Hollenbeck PJ, eds. Advances in Neurology: Tourette Syndrome. Vol 99. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:1-16
4.
Woods D, Marcks B, Flessner C. Management of social and occupational difficulties in persons with Tourette syndrome. In: Woods D, Piacentini J, Walkup JT, eds. Treating Tourette Syndrome and Tic Disorders. New York, NY: Guilford Press; 2007:265-278
5.
Leckman JF, Walker DE, Cohen DJ. Premonitory urges in Tourette's syndrome.  Am J Psychiatry. 1993;150(1):98-1028417589PubMedGoogle Scholar
6.
Jankovic J. Tourette's syndrome.  N Engl J Med. 2001;345(16):1184-119211642235PubMedGoogle ScholarCrossref
7.
Scahill L, Erenberg G, Berlin C,  et al.  Contemporary assessment and pharmacotherapy of Tourette syndrome (2006).  NeuroRx. 2006;3(2):192-206Google ScholarCrossref
8.
Cook C, Blacher J. Evidence-based psychosocial treatments for tic disorders.  Clin Psychol Sci Prac. 2007;14:252-267Google ScholarCrossref
9.
Evers RA, Van De Wetering B. A treatment model for motor tics based on a specific tension reduction technique.  J Behav Ther Exp Psychiatry. 1994;25(3):255-2607852608PubMedGoogle ScholarCrossref
10.
Miguel EC, Coffey BJ, Baer L, Savage CR, Rauch SL, Jenike MA. Phenomenology of intentional repetitive behaviors in obsessive-compulsive disorder and Tourette's disorder.  J Clin Psychiatry. 1995;56(6):246-2557775367PubMedGoogle Scholar
11.
Conelea CA, Woods DW. The influence of contextual factors on tic expression in Tourette's syndrome: a review.  J Psychosom Res. 2008;65(5):487-49618940379PubMedGoogle ScholarCrossref
12.
Woods DW, Piacentini JC, Chang S,  et al.  Managing Tourette's Syndrome: A Behavioral Intervention for Children and Adults. New York, NY: Oxford University Press; 2008
13.
American Psychiatric Association.  Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000
14.
Leckman JF, Riddle MA, Hardin MT,  et al.  The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity.  J Am Acad Child Adolesc Psychiatry. 1989;28(4):566-5732768151PubMedGoogle ScholarCrossref
15.
Peterson A. Psychosocial management of tics and intentional repetitive behaviors associated with Tourette syndrome. In: Woods DW, Piacentini JC, Walkup JT, eds. Treating Tourette Syndrome and Tic Disorders: A Guide for Practitioners. New York, NY: Guilford Press; 2007:154-184
16.
Hanley GP, Iwata B, McCord B. Functional analysis of problem behavior: a review.  J Appl Behav Anal. 2003;36(2):147-18512858983PubMedGoogle ScholarCrossref
17.
Watson TS, Dufrene B, Weaver A, Butler T, Meeks C. Brief antecedent assessment and treatment of tics in the general education classroom.  Behav Modif. 2005;29(6):839-85716204419PubMedGoogle ScholarCrossref
18.
Goetz C, Horn S. The treatment of tics. In: Kurlan R, ed. Handbook of Tourette's Syndrome and Related Tic and Behavioral Disorders. 2nd ed. New York, NY: Marcel Dekker; 2005:411-426
19.
Wilhelm S, Deckersbach T, Coffey BJ, Bohne A, Peterson AL, Baer L. Habit reversal versus supportive psychotherapy for Tourette's disorder: a randomized controlled trial.  Am J Psychiatry. 2003;160(6):1175-117712777279PubMedGoogle ScholarCrossref
20.
Albano AM, Silverman WK. The Anxiety Disorders Interview Schedule for DSM-IV, Child Version: Clinician Manual. New York, NY: Oxford University Press; 1996
21.
Walkup JT, Albano AM, Piacentini J,  et al.  Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety.  N Engl J Med. 2008;359(26):2753-276618974308PubMedGoogle ScholarCrossref
22.
Guy W, ed, Bonato R, edCGI: Clinical Global Impressions. Chevy Chase, MD: National Institute of Mental Health; 1970
23.
Shaffer D, Gould MS, Brasic J,  et al.  A Children's Global Assessment Scale (CGAS).  Arch Gen Psychiatry. 1983;40(11):1228-12316639293PubMedGoogle ScholarCrossref
24.
Chang S, Himle M, Tucker B, Woods D, Piacentini J. Initial psychometric properties of a brief parent-report instrument for assessing tic severity in children with chronic tic disorders.  Child Fam Behav Ther. 2009;31(3):181-191Google ScholarCrossref
25.
Scahill L, Leckman J, Schultz R, Katsovich L, Peterson B. A placebo-controlled trial of risperidone in Tourette syndrome.  Neurology. 2003;60(7):1130-113512682319PubMedGoogle ScholarCrossref
26.
Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome.  J Neurol Neurosurg Psychiatry. 2010;81(1):70-7319726418PubMedGoogle ScholarCrossref
27.
Sallee FR, Kurlan R, Goetz CG,  et al.  Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study.  J Am Acad Child Adolesc Psychiatry. 2000;39(3):292-29910714048PubMedGoogle ScholarCrossref
28.
Borenstein M, Rothstein H, Cohen J. Power and Precision. Teaneck, NJ: Biostat; 1997
29.
Carpenter JR, Kenward MG. Missing Data in Randomised Controlled Trials: A Practical GuideBirmingham, AL: National Institute for Health Research; 2008. http://www.pcpoh.bham.ac.uk/publichealth/methodology/projects/RM03_JH17_MK.shtml. Publication RM03/JH17/MK
30.
Allison PD. Missing Data: University Papers Series on Quantitative Applications in the Social Sciences. Thousand Oaks, CA: Sage; 2001
31.
Brown H, Prescott R. Applied Mixed Models in Medicine. Chichester, England: John Wiley & Sons; 1999
32.
Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.  Pharmacoeconomics. 1999;15(2):141-15510351188PubMedGoogle ScholarCrossref
33.
Himle MB, Woods DW, Piacentini JC, Walkup J. Brief review of habit reversal training for Tourette's syndrome.  J Child Neurol. 2006;21(8):719-72516970874PubMedGoogle ScholarCrossref
34.
Swanson JM, Kraemer HC, Hinshaw SP,  et al.  Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment.  J Am Acad Child Adolesc Psychiatry. 2001;40(2):168-17911211365PubMedGoogle ScholarCrossref
35.
McCracken JT, McGough J, Shah B,  et al; Research Units on Pediatric Psychopharmacology Autism Network.  Risperidone in children with autism and serious behavioral problems.  N Engl J Med. 2002;347(5):314-32112151468PubMedGoogle ScholarCrossref
36.
Pediatric OCD Treatment Study (POTS) Team.  Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.  JAMA. 2004;292(16):1969-197615507582PubMedGoogle ScholarCrossref
37.
Gilbert DL, Buncher CR. Assessment of scientific and ethical issues in two randomized clinical trial designs for patients with Tourette's syndrome: a model for studies of multiple neuropsychiatric diagnoses.  J Neuropsychiatry Clin Neurosci. 2005;17(3):324-33216179653PubMedGoogle ScholarCrossref
38.
Burd L, Kerbeshian J. Treatment-generated problems associated with behavior modification in Tourette disorder.  Dev Med Child Neurol. 1987;29(6):831-8333480256PubMedGoogle Scholar
39.
Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, Arndt S, Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome.  J Am Acad Child Adolesc Psychiatry. 2002;41(3):330-33611886028PubMedGoogle ScholarCrossref
40.
Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial.  J Am Acad Child Adolesc Psychiatry. 2004;43(2):206-21414726728PubMedGoogle ScholarCrossref
41.
Ross MS, Moldofsky H. Comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette syndrome.  Am J Psychiatry. 1978;135(5):585-587347954PubMedGoogle Scholar
42.
Kushner HA. Cursing Brain? The Histories of Tourette Syndrome. Cambridge, MA: Harvard University Press; 1999
43.
Stevens J, Blachly H. Successful treatment of the maladie des tics in Gilles de la Tourette's syndrome.  Am J Dis Child. 1966;112(6):541-545Google Scholar
44.
Baym CL, Corbett BA, Wright SB, Bunge SA. Neural correlates of tic severity and cognitive control in children with Tourette syndrome.  Brain. 2008;131(pt 1):165-179Google Scholar
45.
Church JA, Fair DA, Dosenbach NUF,  et al.  Control networks in paediatric Tourette syndrome show immature and anomalous patterns of functional connectivity.  Brain. 2009;132(1):225-238Google ScholarCrossref
46.
Marsh R, Maia TV, Peterson BS. Functional disturbances within frontostriatal circuits across multiple childhood psychopathologies.  Am J Psychiatry. 2009;166(6):664-67419448188PubMedGoogle ScholarCrossref
47.
Graybiel AM, Canales JJ. The neurobiology of repetitive behaviors: clues to the neurobiology of Tourette syndrome. In: Cohen DJ, Jankovic J, Goetz C, eds. Advances in Neurology: Tourette Syndrome. Vol 99. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:123-13211530422PubMed
48.
Kalanithi PSA, Zheng W, Kataoka Y,  et al.  Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome  Proc Natl Acad Sci U S A. 2005;102(37):13307-1331216131542PubMedGoogle ScholarCrossref
49.
Mink JW. Neurobiology of basal ganglia and Tourette syndrome: basal ganglia circuits and thalamocortical outputs. In: Walkup JT, Mink JW, Hollenbeck PJ, eds. Advances in Neurology: Tourette Syndrome. Vol 99. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:89-98
Original Contribution
May 19, 2010

Behavior Therapy for Children With Tourette Disorder: A Randomized Controlled Trial

Author Affiliations

Author Affiliations: University of California at Los Angeles (Drs Piacentini and Chang); University of Wisconsin–Milwaukee (Dr Woods); Yale Child Study Center, New Haven, Connecticut (Drs Scahill and Dziura); Massachusetts General Hospital/Harvard Medical School, Cambridge (Drs Wilhelm and Deckersbach); University of Texas Health Science Center at San Antonio (Dr Peterson); Johns Hopkins Medical Institutions, Baltimore, Maryland (Drs Ginsburg and Walkup); and the Tourette Syndrome Association, Bayside, New York (Ms Levi-Pearl). Dr Walkup is now with Weill Cornell Medical College, New York, New York.

JAMA. 2010;303(19):1929-1937. doi:10.1001/jama.2010.607
Abstract

Context Tourette disorder is a chronic and typically impairing childhood-onset neurologic condition. Antipsychotic medications, the first-line treatments for moderate to severe tics, are often associated with adverse effects. Behavioral interventions, although promising, have not been evaluated in large-scale controlled trials.

Objective To determine the efficacy of a comprehensive behavioral intervention for reducing tic severity in children and adolescents.

Design, Setting, and Participants Randomized, observer-blind, controlled trial of 126 children recruited from December 2004 through May 2007 and aged 9 through 17 years, with impairing Tourette or chronic tic disorder as a primary diagnosis, randomly assigned to 8 sessions during 10 weeks of behavior therapy (n = 61) or a control treatment consisting of supportive therapy and education (n = 65). Responders received 3 monthly booster treatment sessions and were reassessed at 3 and 6 months following treatment.

Intervention Comprehensive behavioral intervention.

Main Outcome Measures Yale Global Tic Severity Scale (range 0-50, score >15 indicating clinically significant tics) and Clinical Global Impressions–Improvement Scale (range 1 [very much improved] to 8 [very much worse]).

Results Behavioral intervention led to a significantly greater decrease on the Yale Global Tic Severity Scale (24.7 [95% confidence interval {CI}, 23.1-26.3] to 17.1 [95% CI, 15.1-19.1]) from baseline to end point compared with the control treatment (24.6 [95% CI, 23.2-26.0] to 21.1 [95% CI, 19.2-23.0]) (P < .001; difference between groups, 4.1; 95% CI, 2.0-6.2) (effect size = 0.68). Significantly more children receiving behavioral intervention compared with those in the control group were rated as being very much improved or much improved on the Clinical Global Impressions–Improvement scale (52.5% vs 18.5%, respectively; P < .001; number needed to treat = 3). Attrition was low (12/126, or 9.5%); tic worsening was reported by 4% of children (5/126). Treatment gains were durable, with 87% of available responders to behavior therapy exhibiting continued benefit 6 months following treatment.

Conclusion A comprehensive behavioral intervention, compared with supportive therapy and education, resulted in greater improvement in symptom severity among children with Tourette and chronic tic disorder.

Trial Registration clinicaltrials.gov Identifier: NCT00218777

×